Overview

A Study of Atorvo+ in Healthy Adult Participants

Status:
RECRUITING
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
A Phase 1 study will assess the safety, tolerability, and pharmacokinetics of Atorvo+ in healthy adult participants. .
Phase:
PHASE1
Details
Lead Sponsor:
Indication Bioscience LLC
Treatments:
26S proteasome non-ATPase regulatory subunit 13